Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome.

Lieberman SA, Butterfield GE, Harrison D, Hoffman AR

The Journal of clinical endocrinology and metabolism1 Feb 1994Cited by 90 (Europe PMC)

PMID7508949DOI10.1210/jcem.78.2.7508949PepBankPUB-07508949

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with AIDS cachexia, nitrogen balance during the final 3 days of IGF-I treatment was unchanged versus baseline.
In plain wordsIn patients with AIDS cachexia, nitrogen balance during the final 3 days of IGF-I treatment was unchanged versus baseline.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeFinal nitrogen balance
Study
n = 10
Comparator
Baseline
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
Low or high dose · intravenous 12 h daily · 10 daysAs given in this study (human).
Source sentences
Summary
Nitrogen balance and protein turnover (estimated by [13C]leucine and [15N] glycine kinetics) during the final 3 days of treatment were unchanged compared to baseline values, confirming the transient nature of the anabolic response.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894906
02HumanNon-randomized trialEfficacy outcome
In patients with AIDS cachexia, protein turnover during the final 3 days of IGF-I treatment was unchanged versus baseline.
In plain wordsIn patients with AIDS cachexia, protein turnover during the final 3 days of IGF-I treatment was unchanged versus baseline.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeFinal protein turnover
Study
n = 10
Comparator
Baseline
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
Low or high dose · intravenous 12 h daily · 10 daysAs given in this study (human).
Source sentences
Summary
Nitrogen balance and protein turnover (estimated by [13C]leucine and [15N] glycine kinetics) during the final 3 days of treatment were unchanged compared to baseline values, confirming the transient nature of the anabolic response.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894907
03HumanNon-randomized trialMechanism
In patients with AIDS cachexia, repeated IGF-I administration decreased IGF-binding protein-3 levels.
In plain wordsIn patients with AIDS cachexia, repeated IGF-I administration decreased IGF-binding protein-3 levels.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseIGF-binding protein-3
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenous 12 h daily · 10 daysAs given in this study (human).
Source sentences
Summary
Repeated administration of IGF-I decreased IGF-binding protein-3 levels, producing lower intrainfusion levels of IGF-I and limiting its therapeutic efficacy.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894908
04HumanNon-randomized trialPharmacokinetics
In patients with AIDS cachexia, repeated IGF-I administration produced lower intrainfusion IGF-I levels.
In plain wordsIn patients with AIDS cachexia, repeated IGF-I administration produced lower IGF-I levels during infusion.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseIntrainfusion IGF-I
Study
n = 10
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intravenous 12 h daily · 10 daysAs given in this study (human).
Source sentences
Summary
Repeated administration of IGF-I decreased IGF-binding protein-3 levels, producing lower intrainfusion levels of IGF-I and limiting its therapeutic efficacy.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894909
05HumanNon-randomized trialEfficacy outcome
In patients with AIDS cachexia, low-dose IGF-I produced positive cumulative nitrogen retention of 15.42 g.
In plain wordsIn patients with AIDS cachexia, low-dose IGF-I produced positive cumulative nitrogen retention of 15.42 g.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseCumulative nitrogen retention
Study
n: not reported in source
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
Low dose · intravenous 12 h daily · 10 daysAs given in this study (human).
Measurements
Cumulative nitrogen retention
15.42 g
low-dose IGF-I
Reported +/- term for cumulative nitrogen retention
6.37 g
low-dose IGF-I; uncertainty type not stated
Source sentences
Summary
Cumulative nitrogen retention was positive for both dosage groups (low dose, 15.42 +/- 6.37 g; high dose, 3.62 +/- 4.15 g), but a significant increase in daily nitrogen retention occurred only in the low dose group on days 2, 4, 5, 6, and 7.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894902
06HumanNon-randomized trialEfficacy outcome
In patients with AIDS cachexia, high-dose IGF-I produced positive cumulative nitrogen retention of 3.62 g.
In plain wordsIn patients with AIDS cachexia, high-dose IGF-I produced positive cumulative nitrogen retention of 3.62 g.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseCumulative nitrogen retention
Study
n: not reported in source
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
High dose · intravenous 12 h daily · 10 daysAs given in this study (human).
Measurements
Cumulative nitrogen retention
3.62 g
high-dose IGF-I
Reported +/- term for cumulative nitrogen retention
4.15 g
high-dose IGF-I; uncertainty type not stated
Source sentences
Summary
Cumulative nitrogen retention was positive for both dosage groups (low dose, 15.42 +/- 6.37 g; high dose, 3.62 +/- 4.15 g), but a significant increase in daily nitrogen retention occurred only in the low dose group on days 2, 4, 5, 6, and 7.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894903
07HumanNon-randomized trialEfficacy outcome
In patients with AIDS cachexia, low-dose IGF-I significantly increased daily nitrogen retention only on days 2, 4, 5, 6, and 7.
In plain wordsIn patients with AIDS cachexia, low-dose IGF-I increased daily nitrogen retention on days 2, 4, 5, 6, and 7.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseDaily nitrogen retention
Study
n: not reported in source
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
Low dose · intravenous 12 h daily · 10 daysAs given in this study (human).
Source sentences
Summary
Cumulative nitrogen retention was positive for both dosage groups (low dose, 15.42 +/- 6.37 g; high dose, 3.62 +/- 4.15 g), but a significant increase in daily nitrogen retention occurred only in the low dose group on days 2, 4, 5, 6, and 7.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894904
08HumanNon-randomized trialEfficacy outcome
In patients with AIDS cachexia, high-dose IGF-I did not significantly increase daily nitrogen retention.
In plain wordsIn patients with AIDS cachexia, high-dose IGF-I did not significantly increase daily nitrogen retention.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeDaily nitrogen retention
Study
n: not reported in source
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
High dose · intravenous 12 h daily · 10 daysAs given in this study (human).
Source sentences
Summary
Cumulative nitrogen retention was positive for both dosage groups (low dose, 15.42 +/- 6.37 g; high dose, 3.62 +/- 4.15 g), but a significant increase in daily nitrogen retention occurred only in the low dose group on days 2, 4, 5, 6, and 7.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894905
09HumanNon-randomized trialEfficacy outcome
In patients with AIDS cachexia, high-dose IGF-I increased basal metabolic rate.
In plain wordsIn patients with AIDS cachexia, high-dose IGF-I increased basal metabolic rate.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseBasal metabolic rate
Study
n: not reported in source
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
High dose · intravenous 12 h daily · 10 daysAs given in this study (human).
Source sentences
Summary
The basal metabolic rate increased with high dose IGF-I and may have contributed to the lack of anabolic effect.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
Report a problemFND-0750894910

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

10HumanEndogenous levelNon-randomized trialEfficacy outcome
In patients with AIDS, GH produced a smaller increase in circulating IGF-I than in age-matched controls.
In plain wordsIn patients with AIDS, GH produced a smaller increase in natural IGF-I than in age-matched controls.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseIGF-I response to GH
Study
n = 44
Comparator
Age-matched controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Increase in circulating IGF-I after single GH injection
141 micrograms/L
patients with AIDS
Increase in circulating IGF-I after single GH injection
194 micrograms/L
age-matched controls
Reported +/- term for circulating IGF-I increase
15 micrograms/L
patients with AIDS, after a single GH injection; uncertainty type not stated
Reported +/- term for circulating IGF-I increase
15 micrograms/L
age-matched controls, after a single GH injection; uncertainty type not stated
P value for circulating IGF-I increase after GH
< 0.02 unitless
patients with AIDS versus age-matched controls
Patients with AIDS in GH response comparison
21 participants
single GH injection comparison
Age-matched controls in GH response comparison
23 participants
single GH injection comparison
Source sentences
Summary
A single injection of GH produced a smaller increase in circulating IGF-I in 21 patients with AIDS compared to that in 23 age-matched controls (141 +/- 15 vs. 194 +/- 15 micrograms/L; P < 0.02), indicating partial GH resistance.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten subjects received either low or high dose iv recombinant IGF-I 12 h daily for 10 days.
This result measures the body's own IGF-1 (mecasermin). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0750894901

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome.

Summary

Results from this study10

Natural levels measured1

Version history

Subjects

Publication types

MeSH terms